New animal facility for uPA-SCID mouse model with humanized liver
KMT Hepatech, Inc., an Edmonton-based private company, announced the completion of relocation to a newly renovated state-of-the-art animal facility in Edmonton. The new facility has capacity for significant expansion and facilitates ongoing increase in the efficiency and quality of KMT’s services provided using company’s proprietary KMT MouseTM (uPA+/+/SCID mouse with stable human hepatocytes engraftment of up to 95 per cent).